Indonesia has increased import of Chinese Covid vaccines, including CoronaVac, the Sinopharm vaccine and Convidecia.

Vietnam News Agency reported on May 20 that Bio Farma, an Indonesian state-owned pharmaceutical company, is negotiating with Beijing-based Sinovac Biotech Ltd (SVA:NASDAQ GS) on the continued procurement of 120 million doses of CoronaVac, the COVID-19 vaccine produced by Sinovac.

Bio Farma representatives revealed that the mentioned 120 million doses are not part of the 140 million doses of COVID-19 vaccine procurement contract previously agreed upon by both parties.

The Indonesian company will purchase 50 million doses of Convidecia in China for the self-funded vaccination program. Convidecia is a single-dose viral vector vaccine for COVID-19 developed by CanSino Biologics Inc (6185:Hong Kong).

The first 3 million doses of Convidecia are scheduled to arrive in Indonesia between July and September, with the other 2 million doses to arrive in the fourth quarter of this year.

In addition to the CanSino vaccine, Bio Farma is also planning to purchase 7.5 million doses of COVID-19 vaccine from Sinopharm for the vaccine partnership.